Current partner codePEPTIDESDE
NCT07517042·Not applicable·INTERVENTIONAL

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

Status

Recruiting

Phase

Not applicable

Enrollment

420

Locations

13

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited. In addition, the high cost and potential adverse effects of weight-loss medications restrict their prolonged use, and it is unclear whether low dose medication, intensive life style intervention or together can serve as an effective strategy for weight maintenance. This randomized controlled trial aims to evaluate the effectiveness of a 1-year intensive lifestyle intervention, a reduced dose of mazdutide (3.0 mg once weekly), or their combination in weight maintenance among individuals with obesity who have achieved initial weight loss after intensive treatment with high dose mazdutide. The study seeks to provide high-quality clinical evidence to inform long-term weight maintenance strategies after weight loss in patients with obesity.

Interventions

Treatment arms and agents.

DRUG

Mazdutide

Mazdutide is administered subcutaneously at 3.0 mg once weekly for 52 weeks during the weight maintenance period.

BEHAVIORAL

Intensive Lifestyle Intervention

A structured intensive lifestyle intervention including individualized dietary counseling, physical activity guidance, and behavioral modification support for 52 weeks during the weight maintenance period.

Timeline

From registration to results.

  1. First posted

    Apr 8, 2026

  2. Study start

    Apr 2026

  3. Primary completion

    Dec 2028

  4. Study completion

    Dec 2028

  5. Results posted

    Not reported

  6. Registry updated

    Apr 8, 2026

Outcomes

What the study measures.

Primary outcomes

Percentage change of body weight

Time frame · From randomization to Week 52

Secondary outcomes

Change in body mass index (BMI)

Time frame · From randomization to Week 52

Change in waist circumference

Time frame · From randomization to Week 52

Change in total body fat

Time frame · From randomization to Week 52

Change in abdominal visceral fat area

Time frame · From randomization to Week 52

Abdominal visceral fat area is quantified by CT scan

Change in hepatic fat content

Time frame · From randomization to Week 52

Hepatic fat content is quantified by controlled attenuation parameter (CAP), measured by Fibroscan.

Change in blood pressure

Time frame · From randomization to Week 52

Change in serum lipid profile

Time frame · From randomization to Week 52

Changes in blood glucose

Time frame · From randomization to Week 52

Changes in insulin sensitivity

Time frame · From randomization to Week 52

Insulin sensitivity is assessed by HOMA-IR index

Changes in pancreatic β-cell function

Time frame · From randomization to Week 52

Pancreatic β-cell function is assessed by HOMA-β index

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Adult men or women aged 18 years or older; * Simple obesity, defined as a body mass index (BMI) of 28.0-45.0 kg/m²; * Able and willing to provide written informed consent. Exclusion Criteria: * Active pulmonary tuberculosis, malignant tumors, human immunodeficiency virus (HIV) infection, or other serious infectious or systemic diseases; * Severe hepatic impairment (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] \>3 times the upper limit of normal), severe renal impairment, or end-stage renal disease (estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73 m²); * Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months; * Severe gastrointestinal diseases, or a history of gastrointestinal resection surgery within the past year; * Acute or chronic pancreatitis, gallbladder disease, or pancreatic injury; * Obesity secondary to other causes, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, or acromegaly; drug-induced obesity, such as obesity related to the use of antipsychotic agents or glucocorticoids; * Current smoker or habitual smoking within the past 3 months; * Current use of other weight-loss medications or a history of bariatric surgery; * Previously diagnosed diabetes mellitus or current use of glucose-lowering medications; * Pregnant or breastfeeding women, or women planning pregnancy during the study period; * Inability to complete a 2-year follow-up due to health conditions, relocation, or other reasons; * Any other condition deemed by the investigator to make the participant unsuitable for participation in the study.

Study locations

13 registered sites.

China. Showing up to 24 locations stored in the fast local snapshot.

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Fujian Provincial Hospital, Affiliated to Fuzhou University

Fuzhou, Fujian, China

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China

Nanjing First Hospital, Nanjing Medical University

Nanjing, Jiangsu, China

The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University

Suzhou, Jiangsu, China

Huadong Hospital, Fudan University

Shanghai, Shanghai Municipality, China

Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Shanghai Tenth People's Hospital, School of Medicine, Tongji University

Shanghai, Shanghai Municipality, China

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

The Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, China

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Mazdutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.